Benoit Rousseau
@benjcrousseau.bsky.social
MD PhD GI oncologist, genomics and immunology. Assistant Member in Dr Luis Diaz’ Lab. Memorial Sloan Kettering Cancer Center, NY, USA
Runner, husband
Messages are mine and reflect my own opinion.
Runner, husband
Messages are mine and reflect my own opinion.
MMRd cancers are sensitive to ICB. What if we were able to induce a MMRd genotype in MMRp cancer cells using tailored chemical mutagenesis?
Delighted to share our two simultaneously published articles in Cancer Cell Press exploring this fundamental question!
www.sciencedirect.com/science/arti...
Delighted to share our two simultaneously published articles in Cancer Cell Press exploring this fundamental question!
www.sciencedirect.com/science/arti...
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer
Mismatch repair deficient (MMRd) tumors harbor thousands of somatic mutations enriched for insertion–deletion (indels) conferring high sensitivity to …
www.sciencedirect.com
June 12, 2025 at 10:48 PM
MMRd cancers are sensitive to ICB. What if we were able to induce a MMRd genotype in MMRp cancer cells using tailored chemical mutagenesis?
Delighted to share our two simultaneously published articles in Cancer Cell Press exploring this fundamental question!
www.sciencedirect.com/science/arti...
Delighted to share our two simultaneously published articles in Cancer Cell Press exploring this fundamental question!
www.sciencedirect.com/science/arti...
Reposted by Benoit Rousseau
Dr. Violaine Randrian, a visiting investigator at MSK, spoke about a study that evaluated gene-specific outcomes in individuals with #lynchsyndrome treated with immune checkpoint blockade for advanced #cancer at #ASCO25.
June 2, 2025 at 8:05 PM
Dr. Violaine Randrian, a visiting investigator at MSK, spoke about a study that evaluated gene-specific outcomes in individuals with #lynchsyndrome treated with immune checkpoint blockade for advanced #cancer at #ASCO25.
Join us today at ASCO to see the fantastic work of Dr Violaine Randrian investigating what is the impact of different germline variants on outcomes derived from immunotherapy in patients with Lynch syndrome!
@mskcancercenter.bsky.social
@mskcancercenter.bsky.social
June 2, 2025 at 3:03 PM
Join us today at ASCO to see the fantastic work of Dr Violaine Randrian investigating what is the impact of different germline variants on outcomes derived from immunotherapy in patients with Lynch syndrome!
@mskcancercenter.bsky.social
@mskcancercenter.bsky.social
Reposted by Benoit Rousseau
The best in #GIonc trials to look for at #ASCO25. 2⃣ plenary talks that will revolutionize #crcsm and #esocsm #stmcsm. Can't wait to take this best of science into the clinic!
@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social
The #ASCO25 #OncoAlertTOP10 Abstracts in GI Oncology
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸
@realbowtiedoc.bsky.social
@arosen380.bsky.social
Ping
@gillsharlene.bsky.social
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸
@realbowtiedoc.bsky.social
@arosen380.bsky.social
Ping
@gillsharlene.bsky.social
May 26, 2025 at 9:41 AM
The best in #GIonc trials to look for at #ASCO25. 2⃣ plenary talks that will revolutionize #crcsm and #esocsm #stmcsm. Can't wait to take this best of science into the clinic!
@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social
Check out our article published today in the NEJM by Cercek et al. studying 6 months of anti PD1 in MMRd early stage tumors and showing high organ preservation rate pancancer! Very low recurrences and anti PD1 didn’t compromise access to surgery if required. @mskcancercenter.bsky.social
Presented at #AACR25:
Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi
#MedSky @theaacr.bsky.social
Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi
#MedSky @theaacr.bsky.social
April 27, 2025 at 9:14 PM
Check out our article published today in the NEJM by Cercek et al. studying 6 months of anti PD1 in MMRd early stage tumors and showing high organ preservation rate pancancer! Very low recurrences and anti PD1 didn’t compromise access to surgery if required. @mskcancercenter.bsky.social
Reposted by Benoit Rousseau
Join MSK gastrointestinal medical oncologist Dr. Andrea Cercek for a plenary session titled “Non operative management of mismatch repair deficient tumors” TODAY at #AACR25 @theaacr.bsky.social. Learn more: bit.ly/4lUDRS6
April 27, 2025 at 4:50 PM
Join MSK gastrointestinal medical oncologist Dr. Andrea Cercek for a plenary session titled “Non operative management of mismatch repair deficient tumors” TODAY at #AACR25 @theaacr.bsky.social. Learn more: bit.ly/4lUDRS6
Check our editorial with Andrea Cercek in the JCO on stage III colon cancer ! #coloncancer
Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer | Journal of Clinical Oncology ascopubs.org/doi/full/10....
Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer | Journal of Clinical Oncology ascopubs.org/doi/full/10....
ASCO Publications
ascopubs.org
April 12, 2025 at 6:06 PM
Check our editorial with Andrea Cercek in the JCO on stage III colon cancer ! #coloncancer
Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer | Journal of Clinical Oncology ascopubs.org/doi/full/10....
Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer | Journal of Clinical Oncology ascopubs.org/doi/full/10....
Reposted by Benoit Rousseau
A small but heralded #clinicaltrial at @mskcancercenter.bsky.social that saw #rectalcancer disappear in 100% of people who took part has taken a step towards approval by @fda.gov
#cancerresearch #oncsky
#cancerresearch #oncsky
Rectal Cancer Disappears After Experimental Use of Immunotherapy, Now an FDA Designated Breakthrough Therapy
Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.
www.mskcc.org
December 18, 2024 at 11:12 PM
A small but heralded #clinicaltrial at @mskcancercenter.bsky.social that saw #rectalcancer disappear in 100% of people who took part has taken a step towards approval by @fda.gov
#cancerresearch #oncsky
#cancerresearch #oncsky